Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ...

Barclays analyst Andrew Mok CFA maintained a Buy rating on Elevance Health (ELV – Research Report) today and set a price target of $512.00. The ...

Fintel reports that on April 9, 2025, Guggenheim initiated coverage of Elevance Health (NYSE:ELV) with a Buy recommendation.

This compares to the stock's 8% gain over the past four weeks. Elevance Health’s share price benefited from investors seeking stability amid heightened market volatility. A sharp sell-off in ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $477.08, along with a high estimate of $512.00 and a low estimate of $405.40. Marking an ...

Guggenheim initiated coverage of Elevance Health (ELV) with a Buy rating and $518 price target The firm launched coverage on 11 healthcare ...

The good news is that this large sale was at well above current price of US$432 ... So What Does This Data Suggest About Elevance Health Insiders? Insiders sold stock recently, but they haven ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hotchkis & Wiley, an investment management company, released its “Hotchkis & Wiley Large Cap Fundamental Value Fund” fourth ...